Valneva penetrates Chinese Market thanks to a license agreement

18/03/2015 - 2 minutes

A few months ago, the article “An Anglo-French Partnership To Cure Hepatitis B” related Valneva partnerships with Immune Targeting Systems. Today Valneva, a leading pure play vaccines biotech company is again on the front of the stage by announcing the exclusive license agreement with the Chinese company Jianshun Biosciences to commercialize Valneva’s EB66 cell line for the manufacturing of human and veterinary vaccines in People’s Republic of China only.

China, as an emerging vaccine market, represents a major opportunity for Valneva. The government has made it a priority to better protect the population from diseases, especially in endemic areas and China’s vaccine manufacturers are moving ahead to become global suppliers of affordable vaccines. China’s human vaccine market is comprised of 42 vaccine manufacturers and in 2013 the total amount of vaccines manufactured in China added up to nearly 755 million doses. Chinese vaccine manufacturers consist of state-owned enterprises, private enterprises and foreign-funded enterprises.

With this agreement, Valneva remains the full owner of the EB66 platform and will continue to license its technology outside China.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member